Literature DB >> 9023655

In-vitro bactericidal activity of cefpirome in combination with vancomycin against Staphylococcus aureus and coagulase-negative staphylococci.

J Raymond1, G Vedel, M Bergeret.   

Abstract

In an in-vitro study of the bactericidal activity of cefpirome in combination with vancomycin against 11 clinical isolates of staphylococci, cefpirome at a concentration of 0.25 times the MIC acted synergistically with vancomycin (at a concentration of 0.5, 1 or 2 times the MIC) against Staphylococcus aureus and coagulase-negative staphylococci susceptible or resistant to methicillin. Moreover, increasing the cefpirome concentration to 0.5 or 1 times the MIC combined with vancomycin at the same concentration (0.5 or 1 times the MIC) improved the bacterial killing rate; a bactericidal effect was obtained in 9 or 24 h instead of in 24 or 48 h, respectively.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9023655     DOI: 10.1093/jac/38.6.1067

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  4 in total

1.  Pharmacodynamics of cefepime alone and in combination with various antimicrobials against methicillin-resistant Staphylococcus aureus in an in vitro pharmacodynamic infection model.

Authors:  Vanthida Huang; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

Review 2.  Alternative strategies for proof-of-principle studies of antibacterial agents.

Authors:  Axel Dalhoff; Andrej Weintraub; Carl Erik Nord
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

3.  In vitro synergistic effects of double and triple combinations of beta-lactams, vancomycin, and netilmicin against methicillin-resistant Staphylococcus aureus strains.

Authors:  S Rochon-Edouard; M Pestel-Caron; J F Lemeland; F Caron
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

4.  In vitro activity effects of combinations of cephalothin, dicloxacillin, imipenem, vancomycin and amikacin against methicillin-resistant Staphylococcus spp. strains.

Authors:  Guadalupe Miranda-Novales; Blanca E Leaños-Miranda; Mariano Vilchis-Pérez; Fortino Solórzano-Santos
Journal:  Ann Clin Microbiol Antimicrob       Date:  2006-10-12       Impact factor: 3.944

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.